FIELD: pharmaceuticals.
SUBSTANCE: invention relates to compounds of formula 1, where R2 and R3 are defined in the claims, or their pharmaceutically acceptable salts, methods of their preparation, pharmaceutical compositions containing them, and the use of compounds for the treatment and prevention of FAP-mediated diseases.
R1 is selected from:
EFFECT: obtaining pyrrolidine and piperidine compounds.
11 cl, 8 tbl, 439 ex
Title | Year | Author | Number |
---|---|---|---|
IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISORDERS | 2020 |
|
RU2833052C2 |
OXAZOLIDINE-BASED COMPOUND AND ANDROGEN RECEPTOR SELECTIVE AGONIST | 2015 |
|
RU2702001C2 |
DIAMINOPYRIMIDINE DERIVATIVES AND METHODS FOR PRODUCTION THEREOF | 2012 |
|
RU2587493C2 |
NEW PHTHALAZINE DERIVATIVES AND ITS PRODUCTION PROCESS | 2014 |
|
RU2636585C2 |
DIAMINOPYRIMIDINE DERIVATIVES AND METHODS FOR PRODUCTION THEREOF | 2012 |
|
RU2587981C2 |
TLR7/8 ANTAGONISTS AND USE THEREOF | 2019 |
|
RU2833035C2 |
PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEREIN AND ITS APPLICATION | 2009 |
|
RU2514827C2 |
NEW ANTI-DIABETIC AGENTS | 2000 |
|
RU2265012C2 |
BENZOTHIAZOLE COMPOUNDS AND METHODS FOR THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 2018 |
|
RU2778370C2 |
NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATION OF CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | 2015 |
|
RU2684396C2 |
Authors
Dates
2023-09-13—Published
2020-11-05—Filed